AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Connect Biopharma Holdings Ltd (NASDAQ:CNTB)
2.51 USD
-0.150 5.639%Sponsored Reports
Loading...
| Previous Close (in USD) | 2.66 |
|---|---|
| Change | -0.150 5.639% |
| 52 W H/L (in USD) | 3.820/0.685 |
| EBITDA (in USD) | -57.37M |
| PE Ratio | -- |
| Volume | 726222 |
| Diluted Eps TTM | -1.00 |
| Total Assets (in USD) | 56.075M |
|---|---|
| Total Liabilities (in USD) | 14.095M |
| Revenue TTM (in USD) | 0.064M |
| Cash (in USD) | 38.345M |
| Market Cap (in USD) | 151.477 M |
| Revenue Per Share TTM | 0.001 |
| Gross Profit TTM (in USD) | 0.064M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
3580 CARMEL MOUNTAIN ROAD, San Diego, CA, United States, 92130
858 727 1040
Employees: 64
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Wubin Pan M.B.A., Ph.D. | Co-Founder, Pres & Chairman of Directors | 1965 |
| 2. | Dr. Zheng Wei Ph.D. | Co-Founder, CEO & Director | 1964 |
| 3. | Mr. Steven Chan | Chief Financial Officer | 1972 |
| 4. | Mr. Jiang Bian J.D. | Gen. Counsel & Chief Compliance Officer | NA |
| 5. | Dr. Lei Sun Ph.D. | VP of Biologics & Head of CMC | 1964 |
| 6. | Dr. Raul Collazo Ph.D. | VP & Global Head of Medical Affairs | NA |
| 7. | Dr. Malinda V. Longphre Ph.D. | Head of US Clinical Operations | NA |
| 8. | Dr. Chin Lee M.D., M.P.H. | Chief Medical Officer | 1970 |
| 9. | Dr. Wubin Pan M.B.A., Ph.D. | Co-Founder, President & Chairman of the Board of Directors | 1965 |
| 10. | Mr. Jiang Bian J.D. | General Counsel & Chief Compliance Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.600 1.228% | 49.17 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 48.64 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-11.110 2.238% | 498.15 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-3.430 0.514% | 670.06 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -55.283M | -15.405M | -61.986M | -795.018M | -1305.127M |
| Minority Interest | - | - | - | - | - |
| Net Income | -55.48M | -15.628M | -62.106M | -797.055M | -1306.824M |
| Selling General Administrative | 20.34M | 19.229M | 16.054M | 139.444M | 122.445M |
| Gross Profit | 0.064M | 26.033M | -0.988M | - | - |
| Reconciled Depreciation | 0.704M | 0.66M | 0.988M | 6.94M | 4.082M |
| Ebit | -58.074M | -22.452M | -69.056M | -805.589M | -631.436M |
| Ebitda | -57.37M | -21.792M | -68.336M | -762.069M | -1305.083M |
| Depreciation And Amortization | 0.704M | 0.66M | 0.72M | 43.52M | -673.647M |
| Operating Income | -58.074M | -22.452M | -69.056M | -805.589M | -631.436M |
| Other Operating Expenses | 58.138M | 48.485M | 69.056M | 785.217M | 621.47M |
| Interest Expense | - | - | 0.023M | 0.144M | 0.044M |
| Tax Provision | 0.197M | 0.223M | 0.12M | 2.037M | 1.697M |
| Interest Income | 2.268M | 4.453M | 2.714M | 10.715M | 0.622M |
| Net Interest Income | 2.268M | 4.453M | 2.691M | 10.571M | 0.578M |
| Income Tax Expense | 0.197M | 0.223M | 0.12M | 2.037M | 1.697M |
| Total Revenue | 0.064M | 26.033M | 0M | 0M | 0M |
| Total Operating Expenses | 58.138M | 48.485M | 69.056M | 785.217M | 621.47M |
| Cost Of Revenue | - | 0.66M | 0.988M | - | - |
| Total Other Income Expense Net | 2.791M | 7.047M | 7.07M | 10.571M | -673.691M |
| Net Income From Continuing Ops | -55.48M | -15.628M | -59.503M | -797.055M | -1306.824M |
| Net Income Applicable To Common Shares | - | - | - | - | -1306.824M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 56.075M | 101.284M | 125.892M | 1211.93M | 1855.659M |
| Intangible Assets | 0.045M | 0.053M | 0.062M | 22.041M | 22.547M |
| Other Current Assets | 6.426M | 2.202M | - | - | 3.953M |
| Total Liab | 14.095M | 9.118M | 24.849M | 115.06M | 119.828M |
| Total Stockholder Equity | 41.98M | 92.166M | 101.043M | -3175.22M | 1735.831M |
| Other Current Liab | 11.16M | 7.802M | 2.999M | 24.385M | 32.84M |
| Common Stock | 0.01M | 0.01M | 0.01M | 0.066M | 0.066M |
| Capital Stock | 0.01M | 0.01M | 0.01M | 0.066M | 0.066M |
| Retained Earnings | -400.835M | -345.355M | -539.347M | -3175.22M | -2378.165M |
| Good Will | - | - | - | - | -21.987M |
| Other Assets | - | - | - | - | 18.806M |
| Cash | 38.345M | 78.232M | 106.007M | 550.274M | 1706.88M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 13.613M | 8.462M | 24.264M | 108.817M | 114.665M |
| Current Deferred Revenue | 0.167M | 0.164M | 13.32M | - | - |
| Net Debt | -37.655M | -78.054M | -105.542M | -547.276M | -1706.087M |
| Short Term Debt | 0.322M | 0.154M | 0.285M | 1.294M | 0.63M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 0.69M | 0.178M | 0.465M | 2.998M | 0.793M |
| Other Stockholder Equity | 443.996M | 439.177M | 648.258M | -71.186M | 4155.174M |
| Property Plant Equipment | - | - | - | - | 82.158M |
| Total Current Assets | 50.929M | 96.961M | 120.971M | 1084.937M | 1754.135M |
| Long Term Investments | - | - | 0M | 65.744M | - |
| Short Term Investments | 5.997M | 15.476M | 12.646M | 511.25M | 0M |
| Net Receivables | 0.161M | 1.051M | 0.178M | 1.615M | 47.255M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 1.964M | 0.342M | 7.66M | 83.138M | 81.195M |
| Accumulated Other Comprehensive Income | -1.191M | -1.666M | -7.878M | 71.12M | -41.244M |
| Non Currrent Assets Other | 0.646M | 0.033M | 0.132M | 0.237M | 18.806M |
| Non Current Assets Total | 5.146M | 4.323M | 4.921M | 126.993M | 101.524M |
| Capital Lease Obligations | 0.69M | 0.178M | 0.465M | 2.998M | 0.793M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 10.25M | -3.451M | 75.155M | -571.31M | 13.504M |
| Total Cashflows From Investing Activities | 9.818M | -3.451M | 75.155M | - | -34.025M |
| Total Cash From Financing Activities | 1.093M | 0.227M | -0.246M | -0.625M | 1316.099M |
| Net Income | -55.48M | -15.628M | -59.383M | -795.018M | -1305.127M |
| Change In Cash | -39.887M | -27.431M | 26.997M | -1156.606M | 696.804M |
| Begin Period Cash Flow | 78.232M | 105.663M | 79.01M | 1706.88M | 1010.076M |
| End Period Cash Flow | 38.345M | 78.232M | 106.007M | 550.274M | 1706.88M |
| Total Cash From Operating Activities | -51.206M | -23.612M | -47.93M | -679.665M | -544.926M |
| Depreciation | 0.704M | 0.66M | 0.988M | 6.94M | 4.082M |
| Other Cashflows From Investing Activities | 0.775M | 0.123M | -0.084M | - | -22.284M |
| Dividends Paid | - | - | - | - | 0.243M |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | 0M | 0M | -3.674M |
| Other Cashflows From Financing Activities | 1.093M | 0.227M | 75.155M | 0.758M | -110.954M |
| Capital Expenditures | 0.434M | 0.75M | 0.294M | 29.32M | 47.529M |
| Change In Working Capital | 0.58M | -15.49M | 9.485M | 49.023M | 20.82M |
| Other Non Cash Items | -0.736M | 0.118M | -2.279M | -9.248M | 0.044M |
| Free Cash Flow | -51.64M | -24.362M | -48.224M | -708.985M | -592.455M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Inver-99 SICAV | 3 years ago | 15000 |
| 2. | LUX IM Global Medtech HX | 2 years ago | 2500 |
| 3. | SPDR® Portfolio Emerging Markets ETF | 2 years ago | 111 |
| 4. | Fidelity Nasdaq Composite Index | 2 years ago | 27961 |
| 5. | LUX IM Global Medtech HX | 2 years ago | 2500 |
| 6. | SPDR® Portfolio Emerging Markets ETF | 2 years ago | 111 |
| 7. | Fidelity Nasdaq Composite Index | 11 months ago | 23320 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Morgan Stanley - Brokerage Accounts | 2 years ago | 0 |
| 2. | Kynam Capital Management, LP | 2 years ago | 0 |
| 3. | Adage Capital Partners Gp LLC | 2 years ago | 0 |
| 4. | EverSource Wealth Advisors, LLC | 6 months ago | 1288 |
| 5. | ADAR1 Capital Management LLC | 9 months ago | 0 |
| 6. | Royal Bank of Canada | 9 months ago | 0 |
| 7. | Commonwealth Equity Services Inc | 9 months ago | 0 |
| 8. | Rhumbline Advisers | 9 months ago | 0 |
| 9. | Citadel Advisors Llc | 9 months ago | 0 |
| 10. | UBS Group AG | 9 months ago | 0 |
| 11. | BML Capital Management LLC | 9 months ago | 0 |
| 12. | Renaissance Technologies Corp | 9 months ago | 0 |
| 13. | Morgan Stanley - Brokerage Accounts | 9 months ago | 0 |
| 14. | Geode Capital Management, LLC | 9 months ago | 0 |
| 15. | JPMorgan Chase & Co | 9 months ago | 0 |
| 16. | SBI Securities Co Ltd | 9 months ago | 0 |
| 17. | AlphaCore Capital LLC | 9 months ago | 0 |
| 18. | XTX Topco Ltd | 9 months ago | 0 |
| 19. | RSM US WEALTH MANAGEMENT LLC | 9 months ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...